ADCs are revolutionizing oncology. Biointron provides a simple review of how antibody-drug conjugates deliver precision and potent cancer therapies.
ADLM 2025 was held in Chicago, IL, USA, from July 27-31. The Association for Diagnostics & Laboratory Medicine event hosted global leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking science in laboratory me
CHOK1BN: A proven CHO cell line with high productivity, stability, and global compliance. License from Biointron for antibody manufacturing success.
Afucosylated antibodies boost ADCC by enhancing FcγRIIIa binding on NK cells. Biointron highlights their engineering, clinical approvals, and growing therapeutic applications.
Recombinant proteins fuel research and therapy. Biointron explains their design, production, and importance in biotechnology.
Top companies are driving ADC innovation in 2025. Biointron highlights key players advancing antibody-drug conjugate pipelines.
V(D)J recombination generates antibody diversity. Biointron explains its molecular basis and importance in adaptive immunity.
Fc glycans regulate antibody activity. Biointron reviews their role in modulating immune function and therapeutic antibody efficacy.
Bispecifics vs. monoclonals: what’s the difference? Biointron outlines structural contrasts and therapeutic applications of each format.
Antibodies to watch in H2 2025 spotlight innovation. Biointron highlights approvals and breakthroughs shaping the therapeutic landscape.
Humanization enhances antibody safety and efficacy. Biointron reviews CDR grafting and advanced techniques transforming antibody development.
N-linked glycosylation is vital for IgG stability and function. Biointron explains its impact on therapeutic antibodies and clinical performance.
You can also contact us on the Scientist and Science Exchange marketplaces.